Does apixaban reduce major bleeding, thromboembolic events, and mortality compared with warfarin in patients with ESKD and AF on dialysis?
Apixaban, particularly at the standard 5 mg twice daily dose, may be associated with lower risks of major bleeding, thromboembolism, and mortality compared to warfarin in dialysis patients with ESKD and AF.
Among patients with ESKD and AF on dialysis, apixaban use may be associated with a lower risk of major bleeding compared with warfarin, with a standard 5 mg twice a day dose also associated with reductions in thromboembolic and mortality risk.
Siontis et al. (Thu,) studied this question.